Evidence map›Paper›PMID 40755138›Full record

ArticleDisease models & mechanisms2025

Extended passaging of the SKOV3 ovarian cancer cell line leads to two phenotypically different strains.

Eglė Žymantaitė, Migle Gabrielaite, Vita Pašukonienė, Agata Mlynska

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eglė ŽymantaitėLaboratory of Immunology, National Cancer Institute, P. Baublio g. 3B, LT-08406 Vilnius, Lithuania.ORCID 0000-0002-5401-6804
Migle GabrielaiteInstitute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio 7, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-7959-8767
Vita PašukonienėLaboratory of Immunology, National Cancer Institute, P. Baublio g. 3B, LT-08406 Vilnius, Lithuania.ORCID 0000-0002-3395-1158
Agata MlynskaLaboratory of Immunology, National Cancer Institute, P. Baublio g. 3B, LT-08406 Vilnius, Lithuania.ORCID 0000-0002-3646-0258

Funding

European Commission 101151221HORIZON-MSCA-2023-PF-01 101151221Vilnius University MSF-JM-13/2024Vilnius University, Science Promotion Fund for Scientific Projects, 2024-2025 MSF-JM-13/2024
6 · The paper itself

Abstract

Continuous passaging of cancer cell lines can drive phenotypic and genotypic divergence, potentially compromising the reliability of such models. In this study, we show that two late-passage strains (S1 and S2) of ovarian cancer cell line SKOV3, although authenticated via short tandem repeat (STR) profiling as identical, exhibit substantial differences in morphology, transcriptomic signatures, ability to form 3D cultures and chemotherapeutic responses. Notably, S1 formed compact 3D spheroids and exhibited enhanced epithelial-mesenchymal transition (EMT) pathway activity, whereas S2 displayed a more proliferative, MYC-driven phenotype with larger spheroid structures requiring higher seeding densities. Transcriptomic analysis revealed pathways associated with hypoxia, EMT and angiogenesis in 3D culture, highlighting the complexity introduced by dimensionality in tumour modelling. Critically, S1 showed higher sensitivity to doxorubicin than S2 (IC50 of 0.12 µM versus 1.28 µM, P=0.0001), indicating how clonal evolution can confound drug-response assays. Ultimately, our findings suggest that although STR profiling remains essential for cell line authentication, functionally distinct subpopulations can arise and coexist within the same culture, and their isolation may reveal divergent phenotypes that compromise reproducibility in preclinical cancer research.

Indexed as

Ovarian NeoplasmsCell Line, TumorCell ProliferationDoxorubicinEpithelial-Mesenchymal TransitionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPhenotypeSpheroids, CellularDoxorubicinCancer cell linesClonal evolutionLate passagingOvarian cancerSKOV3

Identifiers

PMID40755138
PMCPMC12421797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.